Tenapanor free base

For research use only. Not for therapeutic Use.

  • CAT Number: I009751
  • CAS Number: 1234423-95-0 (free base)
  • Molecular Formula: C50H66Cl4N8O10S2
  • Molecular Weight: 1145.044
  • Purity: ≥95%
Inquiry Now

Tenapanor (CAT: I009751), also known as AZD-1722 and RDX 5791, is a compound that acts as an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3. NHE3 plays a crucial role in sodium regulation in the gastrointestinal tract and kidneys. Tenapanor has demonstrated a promising preclinical safety profile, with no major concerns about side effects. Currently, tenapanor is undergoing clinical trials to evaluate its efficacy and safety for potential therapeutic applications.


Catalog Number I009751
CAS Number 1234423-95-0 (free base)
Synonyms

AZD-1722; AZD 1722; AZD1722; RDX 5791; RDX-5791; RDX5791; Tenapanor free base;3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6

Molecular Formula C50H66Cl4N8O10S2
Purity ≥95%
Target Na+/H+ exchanger 3 (NHE3) inhibitor
Solubility Soluble in DMSO
Storage 0 - 4 °C for short term, or -20 °C for long term
InChI InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)
InChIKey DNHPDWGIXIMXSA-CXNSMIOJSA-N
SMILES O=S(C1=CC=CC([C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)=C1)(NCCOCCOCCNC(NCCCCNC(NCCOCCOCCNS(=O)(C4=CC=CC([C@@H]5CN(C)CC6=C5C=C(Cl)C=C6Cl)=C4)=O)=O)=O)=O
Reference

</br>1: Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.</br>2: Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096.

Request a Quote